Literature DB >> 25720434

Lenvatinib approved for certain thyroid cancers.

.   

Abstract

The FDA approved lenvatinib to treat progressive, differentiated thyroid cancer, potentially offering the most effective treatment to date for a subset of thyroid cancer patients who do not respond to standard therapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25720434     DOI： 10.1158/2159-8290.CD-NB2015-029

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  4 in total

1.  Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.

Authors:  Qingyang Gu; Bin Zhang; Hongye Sun; Qiang Xu; Yexiong Tan; Guan Wang; Qin Luo; Weiguo Xu; Shuqun Yang; Jian Li; Jing Fu; Lei Chen; Shengxian Yuan; Guibai Liang; Qunsheng Ji; Shu-Hui Chen; Chi-Chung Chan; Weiping Zhou; Xiaowei Xu; Hongyang Wang; Douglas D Fang
Journal:  Oncotarget       Date:  2015-08-21

Review 2.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

3.  Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.

Authors:  Husain Yar Khan; James Ge; Misako Nagasaka; Amro Aboukameel; Gabriel Mpilla; Irfana Muqbil; Mark Szlaczky; Mahmoud Chaker; Erkan Baloglu; Yosef Landesman; Ramzi M Mohammad; Asfar S Azmi; Ammar Sukari
Journal:  Int J Mol Sci       Date:  2019-12-29       Impact factor: 5.923

Review 4.  Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer.

Authors:  Prachi Mishra; Dipranjan Laha; Robert Grant; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.